Sequence: CRRRRRRRRFRRGGGG-IMI
| Experiment Id | EXP000480 |
|---|---|
| Paper | Smart, tumor-targeted, and responsive intracellular delivery engineering (STRIDE) nanoplatform: co-d |
| Peptide | OctaR-FRRG-IMI |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | |
| Formulation Format | Lipid nanoparticle (LNP), peptide-modified |
| Formulation Components | Ionizable lipid (DLin-MC3-DMA), DSPC, cholesterol, PEG-lipid; DSPE-PEG2000-peptide conjugate (FRRG-IMI or OctaR-FRRG-IMI); payload: siGLI1 (± Pro-DDP) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | A549/DDP (cisplatin-resistant LUAD); uptake also evaluated in A549; 3D A549/DDP tumor spheroids (MCTS) |
| Animal Model | |
| Administration Route | |
| Output Type | In vitro gene silencing (GLI1 mRNA/protein) after siGLI1 delivery |
| Output Value | |
| Output Units | |
| Output Notes | RFI-LNPs increased cellular uptake (flow cytometry/CLSM) and showed improved endosomal/lysosomal escape (Pearson R decreased from 4h to 6h); siGLI1 delivery suppressed GLI1 mRNA and protein, and downregulated resistance-related proteins. |
| Toxicity Notes | |
| Curation Notes |